Zpráva o ukončení klinického hodnocení NISCI v České republice
| Title in English | Report on the clinical trial termination in the Czech Republic NISCI |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| Citation | |
| Description | The report overviews the clinical trial „Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury“ conducted in the Czech Republic. The trial was terminated in CZE on 4 October 2022. The primary aim of the trial was to assess the efficacy of monoclonal antibody NG-101 in patients with spinal cord injury. The trial sponsor is University Zurich (Switzerland), and the legal representative for the EU is University Hospital Heidelberg (Germany). |